Yu‐Feng Wei

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 613 citations · Full text

Medicine, Oncology, Pharmacology +12

Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report

James Chih‐Hsin Yang, Frances A. Shepherd, Dong‐Wan Kim et al. · Journal of Thoracic Oncology · 2019 · 210 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Myung‐Ju Ahn, Kentaro Tanaka, Luis Paz‐Ares et al. · Journal of Clinical Oncology · 2024 · 182 citations · Full text

Medicine, Oncology, Pharmacology +9

Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study

Gee‐Chen Chang, Chao‐Hua Chiu, Chong‐Jen Yu et al. · The Lancet Respiratory Medicine · 2023 · 158 citations

Medicine, Oncology, Radiology +15

Factors responsible for poor sleep quality in patients with chronic obstructive pulmonary disease

Chih-Hao Chang, Li‐Pang Chuang, Shih‐Wei Lin et al. · BMC Pulmonary Medicine · 2016 · 63 citations · Full text

Medicine, Internal Medicine, Pulmonary Function Testing +14